 |
Discover unspoken
trade-offs in
Managing
hemophilia A1,2 |
|
| Are your patients compromising bleed protection or accepting administration challenges? |
|
| According to the World Federation of Hemophilia, |
patients may trade
administration burden
for bleed protection.2 |
 |
|
 |
Large needles for injections and infusions (23G to 27G)4-6 |
|
|
|
Injection site reactions1 |
|
|
|
Number and quality of accessible veins7 |
|
|
Fear of needles7 |
|
|
|
Potential need for central venous access devices7 |
|
|
|
Storage restrictions9 |
|
|
Time-consuming administration8 |
|
|
|
Requires multiple steps, including mixing product8 |
|
|
|
Concerns carrying medication and supplies when going out9 |
|
|
| Large needles for injections and infusions (23G to 27G)4-6 |
|
| Fear of needles7 |
|
| Time-consuming administration8 |
|
| Injection site reactions1 |
|
| Potential need for central venous access devices7 |
|
| Requires multiple steps, including mixing product8 |
|
| Number and quality of accessible veins7 |
|
| Storage restrictions9 |
|
| Concerns carrying medication and supplies when going out9 |
|
|
| WHAT ADMINISTRATION CHALLENGES DO YOUR PATIENTS FACE IN MANAGING HEMOPHILIA A? |
|
|
|
|
 |
| STAY UP TO DATE WITH THE LATEST INFORMATION |
| Get more updates and communications on hemophilia A from Novo Nordisk as they become available. |
|
|
|
|
| References: |
| 1. |
Data on file. Novo Nordisk Inc; Plainsboro, NJ. |
| 2. |
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition [published correction appears in Haemophilia. 2021;27(4):699]. Haemophilia. 2020;26(suppl 6):1-158. |
| 3. |
Usach I, Martinez R, Festini T, Peris JE. Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site. Adv Ther. 2019;36(11):2986-2996. |
| 4. |
Hemlibra® [package insert]. South San Francisco, CA: Genentech, Inc.; 2024. |
| 5. |
World Federation of Hemophilia. Protocols for the treatment of hemophilia and von Willebrand disease. WFH. April 2008. Accessed January 9, 2025. https://www1.wfh.org/publication/files/pdf-1137.pdf. |
| 6. |
Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Somatosens Mot Res. 2006;23(1-2):37-43. |
| 7. |
Mannucci PM. Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A. Expert Opin Investig Drugs. 2020;29(3):303-309. |
| 8. |
Wiley RE, Khoury CP, Snihur AWK, et al. From the voices of people with haemophilia A and their caregivers: challenges with current treatment, their impact on quality of life and desired improvements in future therapies. Haemophilia. 2019;25(3):433-440. |
| 9. |
Hakimi Z, Ghelani R, Bystrická L, et al. Patient Experience of Living With Hemophilia A: a conceptual model of humanistic and symptomatic experience in adolescents, adults, and children. J Health Econ Outcomes Res. 2024;11(2):95-102. |
|
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1‑877‑744‑2579. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.
© 2025 Novo Nordisk All rights reserved. US24HRBD00098 April 2025 |
 |
|
|
|
